July 16, 2024
2 min watch
We had been unable to course of your request. Please attempt once more later. For those who proceed to have this difficulty please contact customerservice@slackinc.com.
On this video, Eric Winer, MD, discusses the outcomes of analysis into acute myeloid leukemia introduced at ASCO Annual Assembly.
Winer, a medical oncologist at Dana-Farber Most cancers Institute, highlighted a examine that examined a brand new remedy routine of azacitidine and venetoclax (Venclexta, AbbVie) in sufferers with acute myeloid leukemia, utilizing solely 7 days of every.
“By reducing the dose of chemotherapy, one of many issues that this may permit us to do is kind of lower the toxicity, lower the myelosuppression, and additional what it can permit is much less infections in the long term, particularly in a inhabitants that is an older inhabitants,” Winer mentioned.
Printed by:
We had been unable to course of your request. Please attempt once more later. For those who proceed to have this difficulty please contact customerservice@slackinc.com.
